DK0912738T3 - Antigen-bindende-fragmenter der specifikt detekterer cancerceller, nukleotider der koder fragmenterne og anvendelse deraf til profylakse og detektion af cancere - Google Patents
Antigen-bindende-fragmenter der specifikt detekterer cancerceller, nukleotider der koder fragmenterne og anvendelse deraf til profylakse og detektion af cancereInfo
- Publication number
- DK0912738T3 DK0912738T3 DK97929703T DK97929703T DK0912738T3 DK 0912738 T3 DK0912738 T3 DK 0912738T3 DK 97929703 T DK97929703 T DK 97929703T DK 97929703 T DK97929703 T DK 97929703T DK 0912738 T3 DK0912738 T3 DK 0912738T3
- Authority
- DK
- Denmark
- Prior art keywords
- antigen
- fragments
- binding fragments
- prophylaxis
- cancers
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title abstract 5
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 102000036639 antigens Human genes 0.000 title abstract 3
- 108091007433 antigens Proteins 0.000 title abstract 3
- 239000012634 fragment Substances 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title 1
- 238000001514 detection method Methods 0.000 title 1
- 239000002773 nucleotide Substances 0.000 title 1
- 125000003729 nucleotide group Chemical group 0.000 title 1
- 238000011321 prophylaxis Methods 0.000 title 1
- 208000032612 Glial tumor Diseases 0.000 abstract 1
- 206010018338 Glioma Diseases 0.000 abstract 1
- 206010029260 Neuroblastoma Diseases 0.000 abstract 1
- 206010039491 Sarcoma Diseases 0.000 abstract 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 abstract 1
- 229940034982 antineoplastic agent Drugs 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 102000037865 fusion proteins Human genes 0.000 abstract 1
- 108020001507 fusion proteins Proteins 0.000 abstract 1
- 201000001441 melanoma Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 210000005170 neoplastic cell Anatomy 0.000 abstract 1
- 230000009826 neoplastic cell growth Effects 0.000 abstract 1
- 230000001613 neoplastic effect Effects 0.000 abstract 1
- 238000011275 oncology therapy Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 208000000587 small cell lung carcinoma Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Optics & Photonics (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65744996A | 1996-05-22 | 1996-05-22 | |
| PCT/US1997/008962 WO1997044461A2 (en) | 1996-05-22 | 1997-05-22 | Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK0912738T3 true DK0912738T3 (da) | 2008-11-17 |
Family
ID=24637247
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK97929703T DK0912738T3 (da) | 1996-05-22 | 1997-05-22 | Antigen-bindende-fragmenter der specifikt detekterer cancerceller, nukleotider der koder fragmenterne og anvendelse deraf til profylakse og detektion af cancere |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US6207153B1 (enExample) |
| EP (1) | EP0912738B1 (enExample) |
| JP (2) | JP4124486B2 (enExample) |
| KR (1) | KR20000015893A (enExample) |
| CN (1) | CN1201005C (enExample) |
| AT (1) | ATE403001T1 (enExample) |
| AU (1) | AU725238B2 (enExample) |
| BR (1) | BR9710811A (enExample) |
| DE (1) | DE69738868D1 (enExample) |
| DK (1) | DK0912738T3 (enExample) |
| ES (1) | ES2312177T3 (enExample) |
| IL (1) | IL127193A (enExample) |
| NO (1) | NO985150L (enExample) |
| NZ (1) | NZ332566A (enExample) |
| WO (1) | WO1997044461A2 (enExample) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4124486B2 (ja) * | 1996-05-22 | 2008-07-23 | ビベンティア バイオテック インコーポレイテッド | ガン細胞を特異的に検出する抗原結合フラグメント、このフラグメントをコードするヌクレオチド、ならびにガンの予防および検出のためのその使用 |
| US20020122807A1 (en) * | 1998-07-07 | 2002-09-05 | Dan Michael D. | Antigen binding fragments, designated 4B5, that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers |
| AU3544599A (en) * | 1998-01-16 | 1999-08-02 | Paul E. Borchardt | Use of radiolabeled monoclonal igm in therapy for cancer and autoimmune disease |
| US6395511B1 (en) * | 1998-11-27 | 2002-05-28 | Darwin Discovery, Ltd. | Nucleic acids encoding a novel family of TGF-β binding proteins from humans |
| US20040009535A1 (en) | 1998-11-27 | 2004-01-15 | Celltech R&D, Inc. | Compositions and methods for increasing bone mineralization |
| WO2001040292A1 (en) * | 1998-11-27 | 2001-06-07 | Novopharm Biotech Inc. | Antigen-binding fragments specific for tumor associated antigens |
| AUPR395801A0 (en) * | 2001-03-26 | 2001-04-26 | Austin Research Institute, The | Antibodies against cancer |
| US20090123470A1 (en) * | 2001-03-26 | 2009-05-14 | The Macfarlane Burnet Istitute For Medical Research And Public Health Ltd. | Antibodies Against Cancer |
| US7582299B2 (en) * | 2001-04-26 | 2009-09-01 | Biogen Idec Ma Inc. | Cripto-specific antibodies |
| MXPA03009797A (es) * | 2001-04-26 | 2004-01-29 | Biogen Inc | ANTICUERPOS PARA BLOQUEO DE PROTEiNA CRIPTO Y USO DE LOS MISMOS. |
| WO2002094191A2 (en) * | 2001-05-23 | 2002-11-28 | New York University | Detection of alzheimer's amyloid by magnetic resonance imaging |
| WO2003044036A1 (en) * | 2001-11-19 | 2003-05-30 | Applied Molecular Evolution, Inc. | Tumor specific monoclonal antibodies |
| US7115716B2 (en) * | 2001-11-19 | 2006-10-03 | Eli Lilly And Company | Tumor specific monoclonal antibodies |
| AU2003221841A1 (en) | 2002-04-03 | 2003-10-27 | Celltech R And D, Inc. | Association of polymorphisms in the sost gene region with bone mineral density |
| US7041309B2 (en) * | 2002-06-13 | 2006-05-09 | Neuropro Technologies, Inc. | Spinal fusion using an HMG-CoA reductase inhibitor |
| US8029803B2 (en) * | 2002-06-20 | 2011-10-04 | Paladin Labs, Inc. | Chimeric antigens for eliciting an immune response |
| US8025873B2 (en) * | 2002-06-20 | 2011-09-27 | Paladin Labs, Inc. | Chimeric antigens for eliciting an immune response |
| US20040176577A1 (en) * | 2002-09-10 | 2004-09-09 | Eva Rojer | Immunoassays for specific determination of SCCA isoforms |
| MXPA05005921A (es) * | 2002-12-02 | 2005-10-19 | Abgenix Inc | Anticuerpos dirigidos a factor de necrosis tumoral y sus usos. |
| EA015166B1 (ru) | 2003-06-16 | 2011-06-30 | Ю-Си-Би Мэньюфэкчуринг, Инк. | Иммуногенные пептиды склеростина (sost), индуцирующие образование специфических антител |
| US8007805B2 (en) * | 2003-08-08 | 2011-08-30 | Paladin Labs, Inc. | Chimeric antigens for breaking host tolerance to foreign antigens |
| US20050220796A1 (en) * | 2004-03-31 | 2005-10-06 | Dynan William S | Compositions and methods for modulating DNA repair |
| IL161673A0 (en) * | 2004-04-29 | 2004-09-27 | Applied Research Systems | Compositions and methods for therapy of chemotherapy-induced neuropathy |
| KR20070100346A (ko) | 2005-01-05 | 2007-10-10 | 바이오겐 아이덱 엠에이 인코포레이티드 | 크립토 결합 분자 |
| ITMI20050739A1 (it) * | 2005-04-22 | 2006-10-23 | Effebi Spa | Piastrina di connsessione valvola-attuatore |
| US8003108B2 (en) * | 2005-05-03 | 2011-08-23 | Amgen Inc. | Sclerostin epitopes |
| US7592429B2 (en) | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
| EP1948802A4 (en) * | 2005-10-13 | 2009-01-14 | Virexx Medical Corp | CHIMERIC ANTIGEN WITH HEPATITIS C VIRUS POLYPEPTIDE AND FC FRAGMENT FOR CALLING UP AN IMMUNE RESPONSE |
| TW200722436A (en) * | 2005-10-21 | 2007-06-16 | Hoffmann La Roche | A peptide-immunoglobulin-conjugate |
| ES2395103T3 (es) * | 2005-12-21 | 2013-02-08 | Viventia Biotechnologies Inc. | Variantes de Scratch asociados al cáncer |
| WO2008061013A2 (en) * | 2006-11-10 | 2008-05-22 | Amgen Inc. | Antibody-based diagnostics and therapeutics |
| EP2094731A2 (en) * | 2006-11-10 | 2009-09-02 | UCB Pharma S.A. | Anti human sclerostin antibodies |
| CL2008002775A1 (es) | 2007-09-17 | 2008-11-07 | Amgen Inc | Uso de un agente de unión a esclerostina para inhibir la resorción ósea. |
| EP2628486A3 (en) * | 2007-12-14 | 2013-10-30 | Amgen, Inc. | Method for treating bone fracture with anti-sclerostin antibodies |
| US20110110772A1 (en) * | 2009-11-11 | 2011-05-12 | Arrell Douglas J | Turbine Engine Components with Near Surface Cooling Channels and Methods of Making the Same |
| DE102010005485B4 (de) | 2010-01-23 | 2021-11-25 | Dr. Ing. H.C. F. Porsche Aktiengesellschaft | Trägerteil |
| SMT202000095T1 (it) | 2010-05-14 | 2020-03-13 | Amgen Inc | Formulazioni di anticorpi anti-sclerostina ad alta concentrazione |
| US9133272B2 (en) | 2011-03-01 | 2015-09-15 | Amgen Inc. | Bispecific binding agents |
| AU2012236962B2 (en) | 2011-03-25 | 2017-05-11 | Amgen Inc. | Anti-sclerostin antibody crystals and formulations thereof |
| ES2667554T3 (es) | 2011-08-04 | 2018-05-11 | Amgen Inc. | Método para el tratamiento de los defectos de espacio óseo |
| AU2012362898B2 (en) | 2011-12-28 | 2017-11-09 | Amgen, Inc. | Method of treating alveolar bone loss through the use of anti-sclerostin antibodies |
| US9925260B2 (en) | 2012-07-05 | 2018-03-27 | Ucb Pharma S.A. | Treatment for bone diseases |
| UY35148A (es) | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
| HK1215261A1 (zh) | 2013-03-14 | 2016-08-19 | Bayer Healthcare Llc | 針對與肝素複合的抗凝血酶β的單克隆抗體 |
| MX379210B (es) * | 2014-02-07 | 2025-03-10 | Univ Mcmaster | Acoplador trifuncional de antígeno de células t y métodos y usos del mismo. |
| CN107073297B (zh) | 2014-07-08 | 2021-09-14 | 纽约大学 | Tau显像配体和其在Tau蛋白病的诊断和治疗中的用途 |
| MA41142A (fr) | 2014-12-12 | 2017-10-17 | Amgen Inc | Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement |
| JP6913078B2 (ja) | 2015-08-13 | 2021-08-04 | ニューヨーク・ユニバーシティ | タウの短縮型Ａｓｐ４２１エピトープに特異的な、抗体を基にした分子、ならびにタウ異常症の診断および治療におけるそれらの使用 |
| GB201604124D0 (en) | 2016-03-10 | 2016-04-27 | Ucb Biopharma Sprl | Pharmaceutical formulation |
| WO2019071358A1 (en) | 2017-10-12 | 2019-04-18 | Mcmaster University | Y182T MUTATION T CELL ANTIGEN COUPLEUR AND METHODS AND USES THEREOF |
| CN119241705A (zh) | 2018-03-30 | 2025-01-03 | 安姆根有限公司 | C末端抗体变体 |
| US11110123B2 (en) | 2018-07-17 | 2021-09-07 | Triumvira Immunologics Usa, Inc. | T cell-antigen coupler with various construct optimizations |
| US10640562B2 (en) | 2018-07-17 | 2020-05-05 | Mcmaster University | T cell-antigen coupler with various construct optimizations |
| CN113621617B (zh) * | 2020-04-21 | 2023-06-20 | 北京仁诚神经肿瘤生物技术工程研究中心有限公司 | cDNA、mRNA、蛋白及评价胶质瘤预后性的试剂盒和系统 |
| US12016923B2 (en) | 2021-06-01 | 2024-06-25 | Triumvira Immunologics Usa, Inc. | Claudin 18.2 T cell-antigen couplers and uses thereof |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
| US3939350A (en) | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4277437A (en) | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
| US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
| DE3343530A1 (de) | 1983-12-01 | 1985-06-13 | Max Planck Gesellschaft | Arzneimittel mit verbesserter penetration der gewebsmembran |
| US5474755A (en) | 1984-01-31 | 1995-12-12 | Akzo Nobel N.V. | Tumor associated monoclonal antibodies |
| US4754065A (en) | 1984-12-18 | 1988-06-28 | Cetus Corporation | Precursor to nucleic acid probe |
| US4618477A (en) | 1985-01-17 | 1986-10-21 | International Business Machines Corporation | Uniform plasma for drill smear removal reactor |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
| US5017566A (en) | 1987-12-30 | 1991-05-21 | University Of Florida | Redox systems for brain-targeted drug delivery |
| US5002935A (en) | 1987-12-30 | 1991-03-26 | University Of Florida | Improvements in redox systems for brain-targeted drug delivery |
| JPH01207920A (ja) | 1988-02-16 | 1989-08-21 | Oki Electric Ind Co Ltd | ＩｎＰ半導体薄膜の製造方法 |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| CA2025907A1 (en) | 1989-09-21 | 1991-03-22 | Franklin D. Collins | Method of transporting compositions across the blood brain barrier |
| US5270202A (en) | 1989-11-03 | 1993-12-14 | Syamal Raychaudhuri | Anti-idiotypic antibodies to human melanoma-associated proteoglycan antigen |
| JPH04346792A (ja) * | 1991-05-22 | 1992-12-02 | Hagiwara Yoshihide | 抗癌ヒトモノクローナル抗体のアミノ酸配列及びそれをコードするｄｎａ塩基配列 |
| CA2120153C (en) | 1991-09-30 | 2006-06-06 | Ira Pastan | Recombinant immunotoxins |
| US5621083A (en) * | 1991-11-04 | 1997-04-15 | Xoma Corporation | Immunotoxins comprising ribosome-inactivating proteins |
| US5639863A (en) * | 1994-06-21 | 1997-06-17 | Dan; Michael D. | Human monoclonal antibodies specific to cell cycle independent glioma surface antigen |
| CU22615A1 (es) | 1994-06-30 | 2000-02-10 | Centro Inmunologia Molecular | Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos |
| JP4124486B2 (ja) | 1996-05-22 | 2008-07-23 | ビベンティア バイオテック インコーポレイテッド | ガン細胞を特異的に検出する抗原結合フラグメント、このフラグメントをコードするヌクレオチド、ならびにガンの予防および検出のためのその使用 |
-
1997
- 1997-05-22 JP JP54285397A patent/JP4124486B2/ja not_active Expired - Fee Related
- 1997-05-22 US US08/862,124 patent/US6207153B1/en not_active Expired - Lifetime
- 1997-05-22 DE DE69738868T patent/DE69738868D1/de not_active Expired - Lifetime
- 1997-05-22 IL IL127193A patent/IL127193A/en not_active IP Right Cessation
- 1997-05-22 AU AU33696/97A patent/AU725238B2/en not_active Revoked
- 1997-05-22 WO PCT/US1997/008962 patent/WO1997044461A2/en not_active Ceased
- 1997-05-22 BR BR9710811A patent/BR9710811A/pt not_active Application Discontinuation
- 1997-05-22 AT AT97929703T patent/ATE403001T1/de not_active IP Right Cessation
- 1997-05-22 EP EP97929703A patent/EP0912738B1/en not_active Expired - Lifetime
- 1997-05-22 CN CNB971948151A patent/CN1201005C/zh not_active Expired - Fee Related
- 1997-05-22 NZ NZ332566A patent/NZ332566A/xx unknown
- 1997-05-22 KR KR1019980709444A patent/KR20000015893A/ko not_active Withdrawn
- 1997-05-22 DK DK97929703T patent/DK0912738T3/da active
- 1997-05-22 ES ES97929703T patent/ES2312177T3/es not_active Expired - Lifetime
-
1998
- 1998-11-04 NO NO985150A patent/NO985150L/no not_active Application Discontinuation
-
2001
- 2001-02-13 US US09/782,397 patent/US20030021779A1/en not_active Abandoned
-
2003
- 2003-08-29 US US10/651,453 patent/US7166286B2/en not_active Expired - Fee Related
-
2007
- 2007-09-25 JP JP2007248260A patent/JP2008099684A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| NO985150L (no) | 1999-01-20 |
| IL127193A (en) | 2006-10-31 |
| US20030021779A1 (en) | 2003-01-30 |
| EP0912738B1 (en) | 2008-07-30 |
| JP2000511421A (ja) | 2000-09-05 |
| EP0912738A2 (en) | 1999-05-06 |
| NO985150D0 (no) | 1998-11-04 |
| DE69738868D1 (de) | 2008-09-11 |
| US6207153B1 (en) | 2001-03-27 |
| AU3369697A (en) | 1997-12-09 |
| ES2312177T3 (es) | 2009-02-16 |
| ATE403001T1 (de) | 2008-08-15 |
| WO1997044461A3 (en) | 1998-05-07 |
| IL127193A0 (en) | 1999-09-22 |
| US20040091484A1 (en) | 2004-05-13 |
| KR20000015893A (ko) | 2000-03-15 |
| NZ332566A (en) | 2000-08-25 |
| WO1997044461A2 (en) | 1997-11-27 |
| AU725238B2 (en) | 2000-10-12 |
| JP2008099684A (ja) | 2008-05-01 |
| JP4124486B2 (ja) | 2008-07-23 |
| CN1201005C (zh) | 2005-05-11 |
| US7166286B2 (en) | 2007-01-23 |
| HK1022174A1 (en) | 2000-07-28 |
| BR9710811A (pt) | 1999-08-17 |
| CN1229436A (zh) | 1999-09-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK0912738T3 (da) | Antigen-bindende-fragmenter der specifikt detekterer cancerceller, nukleotider der koder fragmenterne og anvendelse deraf til profylakse og detektion af cancere | |
| NO331072B1 (no) | Sammensetning som omfatter et angiogenese inhiberende middel og et anti tumor-immunoterapeutisk middel samt anvendelser av det samme. | |
| WO1999002545A3 (en) | Antigen binding fragments, designated 4b5, that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers | |
| NO913211L (no) | Nytt monoklonalt antistoff mot nytt antigen knyttet til menneske-tumorer. | |
| NO20030211L (no) | Blandinger og fremgangsmåter for terapi og diagnose av ovariekreft | |
| HUP0500345A2 (hu) | Készítmények és alkalmazások tüdőrák kezelésére és diagnosztizálására | |
| ES2061730T3 (es) | Nuevos anticuerpos. | |
| DE69419721D1 (de) | Rekombinante anti-vla4 antikörpermoleküle | |
| EP2196474A3 (en) | Therapeutic targets in cancer | |
| RU2008128244A (ru) | Способы идентификации опухолей, восприимчивых к лечению антителами против erbb2 | |
| NZ594466A (en) | Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies | |
| WO2002083171A3 (en) | Cancer treatment by using fap-alpha specific antibodies | |
| WO2004058146A3 (en) | Novel compositions and methods in cancer | |
| DE69737788D1 (de) | Reagenzien und methoden zum nachweis von erkrankungen der brust | |
| WO2004060304A3 (en) | Novel compositions and methods in cancer | |
| ATE180974T1 (de) | Zusammensetzungen und methoden zur behandlung von kleinzell und nicht-kleinzell lungenkrebsen | |
| WO2003080808A3 (en) | Novel compositions and methods in cancer | |
| MacManus et al. | The presence in human tumours of a Mr 11,700 calciumdashbinding protein similar to rodent oncomodulin | |
| CA2255540A1 (en) | Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers | |
| ATE449171T1 (de) | Reagentia und verfahren zum nachweis von brustkrankheiten | |
| Croce et al. | Identification of acute-phase proteins (APP) in circulating immune complexes (CIC) in esophageal cancer patients' sera | |
| Wust et al. | Antibody-dependent cytolysis of the human leukemia cell line K-562 in the absence of effector cells or complement | |
| Zusman et al. | HPLC determination of serum levels of soluble p53 antigen as a new method for colon cancer detection, and its clinical implication | |
| WO2004060301A3 (en) | Novel compositions and methods in cancer | |
| Knapp et al. | Oncofoetal pancreatic antigen |